Why pharma firms are betting billions on psychedelic drugs despite setbacks

T1Covered by 1 source · first reported by Nature / Science / Nature Biotechnology at 27 Oct, 00:00 UTC

Nature, Published online: 27 October 2026; doi:10.1038/d41586-026-03390-8 Regulatory pushback stalled the field. But researchers are optimistic about mind-altering drugs as potential treatments for depression and mood disorders.